Related references
Note: Only part of the references are listed.Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins
Michael J. Satlin
CLINICAL INFECTIOUS DISEASES (2021)
Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals
Jeffrey R. Strich et al.
CLINICAL INFECTIOUS DISEASES (2021)
Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region
Brian D. Johnston et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
Use of colistin in adult patients: A cross-sectional study
Daniele Roberto Giacobbe et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in US Hospitals during 2016 to 2018
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America
Helio S. Sader et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Evaluation of Eravacycline: A Novel Fluorocycline
Sara Alosaimy et al.
PHARMACOTHERAPY (2020)
Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
Sara Alosaimy et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales
Beatriz Dietl et al.
FUTURE MICROBIOLOGY (2020)
European intensive care physicians' experience of infections due to antibiotic-resistant bacteria
Alain Lepape et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2020)
Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It
Zeinab Breijyeh et al.
MOLECULES (2020)
Modern Tools for Rapid Diagnostics of Antimicrobial Resistance
Antti Vasala et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
No money for new drugs
Benjamin Plackett
NATURE (2020)
Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN)
Stephen Hughes et al.
JAC-ANTIMICROBIAL RESISTANCE (2020)
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2019)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2019)
Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam - β-Lactamase Inhibitor Combination
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
Keith S. Kaye et al.
CLINICAL INFECTIOUS DISEASES (2019)
By ZEUS! Can We Use Intravenous Fosfomycin for Complicated Urinary Tract Infections?
Patrick N. A. Harris
CLINICAL INFECTIOUS DISEASES (2019)
Antimicrobial treatment challenges in the era of carbapenem resistance
Anna Maria Peri et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections
Khalid Eljaaly et al.
DRUGS (2019)
Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017
Simone Iacchini et al.
EUROSURVEILLANCE (2019)
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
James A. McKinnell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Florian M. E. Wagenlehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Chau-Chyun Sheu et al.
FRONTIERS IN MICROBIOLOGY (2019)
Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
Tianshui Niu et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2019)
Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
Chun-Hsing Liao et al.
INFECTION AND DRUG RESISTANCE (2019)
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
Christopher Frohlich et al.
MSPHERE (2019)
Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia
Jien-Wei Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship
Shio-Shin Jean et al.
DRUGS (2019)
Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC
Melissa D. Barnes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Bloodstream infections caused by multidrug-resistant gram-negative bacteria: epidemiological, clinical and microbiological features
Helena Ferreira Leal et al.
BMC INFECTIOUS DISEASES (2019)
Eravacycline, a newly approved fluorocycline
Young Ran Lee et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
The Old and the New Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Ilias Karaiskos et al.
FRONTIERS IN PUBLIC HEALTH (2019)
Combating resistance while maintaining innovation: the future of antimicrobial stewardship
Richard J. Vickers et al.
FUTURE MICROBIOLOGY (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Crisis of Antimicrobial Resistance in China: Now and the Future
Junyan Qu et al.
FRONTIERS IN MICROBIOLOGY (2019)
Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
Matteo Bassetti et al.
INFECTION AND DRUG RESISTANCE (2019)
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections
Joseph S. Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2019)
Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens
Ilias Karaiskos et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
Alessandro Cassini et al.
LANCET INFECTIOUS DISEASES (2019)
Antimicrobial Resistance in the Asia Pacific region: a meeting report
Esabelle Lo Yan Yam et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2019)
Management of Urosepsis in 2018
Gernot Bonkat et al.
EUROPEAN UROLOGY FOCUS (2019)
Polymyxins: To Combine or Not to Combine?
Federico Perez et al.
ANTIBIOTICS-BASEL (2019)
Treatment of Infections Due to MDR Gram-Negative Bacteria
Matteo Bassetti et al.
FRONTIERS IN MEDICINE (2019)
Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria
Emily M. Eichenberger et al.
ANTIBIOTICS-BASEL (2019)
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections
Gregory G. Stone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
NICE Guidance - Complicated urinary tract infections: ceftolozane/tazobactam
[Anonymous]
BJU INTERNATIONAL (2018)
Pharmacokinetic drug evaluation of avibactam plus ceftazidime for the treatment of hospital-acquired pneumonia
Marco Falcone et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward molecularly targeted' therapy
Nadim G. El Chakhtoura et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria
Twisha S. Patel et al.
FUTURE MICROBIOLOGY (2018)
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection
Maddalena Giannella et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey
Kevin Diallo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party
Peter M. Hawkey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactann Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
Krisztina M. Papp-Wallace et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
F. Chaves et al.
MEDICINA INTENSIVA (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing EnterobacteriaceaeN 10.1093/jac/dky323
Jiachun Su et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Quantifying drivers of antibiotic resistance in humans: a systematic review
Anuja Chatterjee et al.
LANCET INFECTIOUS DISEASES (2018)
New Antibiotics for Pneumonia
Matteo Bassetti et al.
CLINICS IN CHEST MEDICINE (2018)
Fosfomycin: what was old is new again
Minyon L. Avent et al.
INTERNAL MEDICINE JOURNAL (2018)
Discovery of mcr-1-Mediated Colistin Resistance in a Highly Virulent Escherichia coli Lineage
Brian M. Forde et al.
MSPHERE (2018)
Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum -Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review
Daniel B. Chastain et al.
ANNALS OF PHARMACOTHERAPY (2018)
Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia
Antoni Torres et al.
ERJ OPEN RESEARCH (2018)
Addressing the Unknowns of Antimicrobial Resistance: Quantifying and Mapping the Drivers of Burden
Gwenan M. Knight et al.
CLINICAL INFECTIOUS DISEASES (2018)
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
Antoni Torres et al.
CRITICAL CARE (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
Antoni Torres et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Federico Pea et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
Patrick N. A. Harris et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial
Joseph Solomkin et al.
JAMA SURGERY (2017)
The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections
Massimo Sartelli et al.
WORLD JOURNAL OF EMERGENCY SURGERY (2017)
Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials
Elizabeth L. Alexander et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group
Diana Averbuch et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
Jose M. Munita et al.
CLINICAL INFECTIOUS DISEASES (2017)
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study
Eliana S. Armstrong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Belen Gutierrez-Gutierrez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
Andre C. Kalil et al.
CLINICAL INFECTIOUS DISEASES (2016)
Understanding the mechanisms and drivers of antimicrobial resistance
Alison H. Holmes et al.
LANCET (2016)
Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia
Nuntra Suwantarat et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2016)
Piperacillin concentration in relation to therapeutic range in critically ill patients - a prospective observational study
Johannes Zander et al.
CRITICAL CARE (2016)
Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?
Matteo Bassetti et al.
CRITICAL CARE (2016)
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
A review on colistin nephrotoxicity
Atefeh Ordooei Javan et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
Helio S. Sader et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
Gennaro De Pascale et al.
CRITICAL CARE (2014)
The ABCD's of β-lactamase nomenclature
Karen Bush
JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L. Silvia Munoz-Price et al.
LANCET INFECTIOUS DISEASES (2013)
Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials
Paritosh Prasad et al.
CLINICAL INFECTIOUS DISEASES (2012)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Fosfomycin: Use beyond urinary tract and gastrointestinal infections
Matthew E. Falagas et al.
CLINICAL INFECTIOUS DISEASES (2008)
Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia
D Panidis et al.
CHEST (2005)
Share Paper
